文献速递肿瘤 PET/CT

18F-FDG PET/CT预测或监测转移性黑色素瘤患者免疫治疗反应的价值:系统综述与Meta分析

The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-07-29

该系统综述与Meta分析纳入24篇文献,评估基线18F-FDG PET/CT参数及传统与改良反应评估标准对转移性黑色素瘤免疫治疗反应的预测与监测价值。基线SUVpeak、MTV和TLG是最终反应的有前景预测因子;改良标准在早期和晚期扫描中灵敏度均高于传统标准;PET可检测的免疫相关不良事件与治疗反应相关。

要点

  • 基线MTV、SLR、SUVpeak和TLG与总生存相关,SUVmax与总生存无显著相关。
  • 早期18F-FDG PET/CT扫描中,改良标准灵敏度94%,传统标准64%。
  • PET可检测的免疫相关不良事件与治疗反应相关。

核心结论

  • 基线SUVpeak、MTV和TLG是转移性黑色素瘤患者免疫治疗最终反应的有前景预测因子。
  • 改良反应评估标准可能是监测免疫治疗的合适方法。
  • 免疫相关不良事件对预测治疗最终临床获益也有价值。

研究设计与样本

  • 系统综述与Meta分析,全面检索评估18F-FDG PET/CT监测转移性黑色素瘤免疫治疗反应预后价值的研究,并筛选入选文献参考文献。
  • 共纳入24篇合格文献,提取详细数据并分类,使用Comprehensive Meta-Analysis软件分析。

主要发现

  • 基于基线18F-FDG PET/CT,MTV对总生存的合并HR为1.777(95%CI:1.389-2.275,p<0.001)。
  • 基于基线18F-FDG PET/CT,SLR对总生存的合并HR为3.425(95%CI:1.707-6.869,p=0.001)。
  • 基于基线18F-FDG PET/CT,SUVmax对总生存的合并HR为0.941(95%CI:0.599-1.477,p=0.791)。
  • 基于基线18F-FDG PET/CT,SUVpeak对总生存的合并HR为1.704(95%CI:1.253-2.316,p=0.016)。
  • 基于基线18F-FDG PET/CT,TLG对总生存的合并HR为1.755(95%CI:1.315-2.342,p<0.001)。

关键数值与推荐

  • 早期18F-FDG PET/CT扫描,传统标准合并灵敏度64%(95%CI:46-79%),改良标准合并灵敏度94%(95%CI:81-99%)。
  • 早期18F-FDG PET/CT扫描,传统标准合并特异度80%(95%CI:59-93%),改良标准合并特异度84%(95%CI:64-95%)。
  • 晚期18F-FDG PET/CT扫描,传统标准合并灵敏度67%(95%CI:35-90%),改良标准合并灵敏度92%(95%CI:73-99%)。
  • 晚期18F-FDG PET/CT扫描,传统标准合并特异度77%(95%CI:56-91%),改良标准合并特异度76%(95%CI:50-93%)。
  • PET可检测的免疫相关不良事件与治疗反应相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the ability of 18F-FDG PET/CT to assess the response of patients with metastatic melanoma to immunotherapy. METHODS: A comprehensive search of the literature for studies examining the prognostic value of 18F-FDG PET/CT in monitoring the response of patients with metastatic melanoma to immunotherapy was performed. We also screened the references of the selected articles to identify any other relevant studies. Detailed data were extracted and categorized. Comprehensive meta-analysis software was used for analysis. RESULTS: Twenty four eligible articles were included in the systematic review. Based on the baseline 18F-FDG PET/CT imaging, the pooled hazard ratios of MTV, SLR, SUV/SULmax, SUV/SULpeak, and TLG for overall survival (OS) were 1.777 (95%CI: 1.389-2.275, p < 0.001), 3.425 (95%CI: 1.707-6.869, p = 0.001), 0.941 (95%CI: 0.599-1.477, p = 0.791), 1.704 (95%CI: 1.253-2.316, p = 0.016), and 1.755 (95%CI: 1.315-2.342, p < 0.001), respectively. The conventional and modified response assessment criteria exhibited a pooled sensitivity of 64% (95%CI: 46-79%) and 94% (95%CI: 81-99%) and a pooled specificity of 80% (95%CI: 59-93%) and 84% (95%CI: 64-95%), respectively, for the early 18F-FDG PET/CT scan. On the other hand, based on the late 18F-FDG PET/CT scan, the pooled sensitivity of 67% (95%CI: 35-90%) and 92% (95%CI: 73-99%) and pooled specificity of 77% (95%CI: 56-91%) and 76% (95%CI: 50-93%) were observed for the conventional and modified criteria, respectively. PET-detectable immune-related adverse events (irAEs) were associated with the response to therapy. CONCLUSIONS: The baseline SUVpeak, MTV, and TLG parameters represent promising predictors of the final response of metastatic melanoma patients to immunotherapy. Modified response assessment criteria are potentially an appropriate method for monitoring immunotherapy. irAEs are also valuable for predicting eventual clinical benefit of treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ayati N, Sadeghi R, Kiamanesh Z, et al. The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2020. PMID: 32728798. doi:10.1007/s00259-020-04967-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。